| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aea57db10fe6e572d4a54808447081e9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-147777
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-38 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01V1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01V1-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01V1-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate |
2010-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aea1f55945d48d8c2238317cd0c33095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_def065141b928fc4e5773259d7113d5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9755df8cd9b2c671441665f96aeda2dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17bdf0559a425282e77af6af2aaf6228 |
| publicationDate |
2011-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2011010565-A |
| titleOfInvention |
USE OF TETRAHYDROBIOPTERINE AS A MARKER AND THERAPEUTIC AGENT FOR FABRY'S DISEASE. |
| abstract |
Blood and tissue markers of metabolic status, risk of health complications in patients with Fabry disease and as a biomarker to measure the efficacy of treatment in model animals and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites are described of BH4 and other related co-factors. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, curb or reverse vascular and renal cardiac manifestations of Fabry disease. |
| priorityDate |
2009-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |